A first-in-human phase I clinical trial was launched in 2012 to investigate the safety, pharmacodynamics and -kinetics, as well as the immunogenicity of repeated doses of CSL362 in patients with CD123+ AML currently in complete remission or complete remission with incomplete platelet recovery at high risk of early relapse (ClinicalTrials.gov Identifier: NCT01632852). The gene discussed is IL3RA; the disease is acute myeloid leukemia.